Therapeutic strategy of targeting astrocytes for neuroprotection in parkinson’s disease

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Parkinson’s disease (PD) is one of common neurodegenerative diseases, which shows motor symptoms including tremor, bradykinesia, rigidity and postural instability. It also involves non-motor symptoms such as cognitive impairment, mental manifestation, autonomic disorder and sensory disturbance. Although treatments to improve the motor disability in PD are being assessed at present, the main challenge remains that is the development of neuroprotective or disease-modifying treatments. Therefore, it is desirable to find approaches that can inhibit the progression of dopaminergic neurodegeneration. Astrocytes are known to play an important role in the maintenance of the neuronal environment and exert neuroprotective effects. Additionally, astrocyte dysfunction increases the susceptibility of neurons to cytotoxicity. We have demonstrated neuroprotective approaches in parkinsonian models in various studies targeting astrocytes. In this article, we summarize the neuroprotective function of astrocytes in the brain, involvement of astrocyte dysfunction in neurodegeneration, and experimental approaches to dopaminergic neuroprotection. We review findings reported in several papers including our own studies. We also address target molecules and pivotal pathways in astrocytes for dopaminergic neuroprotection. The review discusses new promising therapeutic strategies to prevent dopaminergic neurodegeneration in PD.

Original languageEnglish
Pages (from-to)4936-4947
Number of pages12
JournalCurrent Pharmaceutical Design
Volume23
Issue number33
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Astrocytes
Parkinson Disease
Therapeutics
Sensation Disorders
Hypokinesia
Neuroprotective Agents
Tremor
Neurodegenerative Diseases
Neuroprotection
Maintenance
Neurons
Brain

Keywords

  • 5-hT1A receptor
  • Antioxidative molecules
  • Astrocyte
  • Dopaminergic neuron
  • Neuroprotection
  • Nrf2
  • Parkinson’s disease
  • XCT

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Therapeutic strategy of targeting astrocytes for neuroprotection in parkinson’s disease. / Miyazaki, Ikuko; Asanuma, Masato.

In: Current Pharmaceutical Design, Vol. 23, No. 33, 01.01.2017, p. 4936-4947.

Research output: Contribution to journalReview article

@article{9f8b5ae3b5914642bedae8d91bff7178,
title = "Therapeutic strategy of targeting astrocytes for neuroprotection in parkinson’s disease",
abstract = "Parkinson’s disease (PD) is one of common neurodegenerative diseases, which shows motor symptoms including tremor, bradykinesia, rigidity and postural instability. It also involves non-motor symptoms such as cognitive impairment, mental manifestation, autonomic disorder and sensory disturbance. Although treatments to improve the motor disability in PD are being assessed at present, the main challenge remains that is the development of neuroprotective or disease-modifying treatments. Therefore, it is desirable to find approaches that can inhibit the progression of dopaminergic neurodegeneration. Astrocytes are known to play an important role in the maintenance of the neuronal environment and exert neuroprotective effects. Additionally, astrocyte dysfunction increases the susceptibility of neurons to cytotoxicity. We have demonstrated neuroprotective approaches in parkinsonian models in various studies targeting astrocytes. In this article, we summarize the neuroprotective function of astrocytes in the brain, involvement of astrocyte dysfunction in neurodegeneration, and experimental approaches to dopaminergic neuroprotection. We review findings reported in several papers including our own studies. We also address target molecules and pivotal pathways in astrocytes for dopaminergic neuroprotection. The review discusses new promising therapeutic strategies to prevent dopaminergic neurodegeneration in PD.",
keywords = "5-hT1A receptor, Antioxidative molecules, Astrocyte, Dopaminergic neuron, Neuroprotection, Nrf2, Parkinson’s disease, XCT",
author = "Ikuko Miyazaki and Masato Asanuma",
year = "2017",
month = "1",
day = "1",
doi = "10.2174/1381612823666170710163731",
language = "English",
volume = "23",
pages = "4936--4947",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "33",

}

TY - JOUR

T1 - Therapeutic strategy of targeting astrocytes for neuroprotection in parkinson’s disease

AU - Miyazaki, Ikuko

AU - Asanuma, Masato

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Parkinson’s disease (PD) is one of common neurodegenerative diseases, which shows motor symptoms including tremor, bradykinesia, rigidity and postural instability. It also involves non-motor symptoms such as cognitive impairment, mental manifestation, autonomic disorder and sensory disturbance. Although treatments to improve the motor disability in PD are being assessed at present, the main challenge remains that is the development of neuroprotective or disease-modifying treatments. Therefore, it is desirable to find approaches that can inhibit the progression of dopaminergic neurodegeneration. Astrocytes are known to play an important role in the maintenance of the neuronal environment and exert neuroprotective effects. Additionally, astrocyte dysfunction increases the susceptibility of neurons to cytotoxicity. We have demonstrated neuroprotective approaches in parkinsonian models in various studies targeting astrocytes. In this article, we summarize the neuroprotective function of astrocytes in the brain, involvement of astrocyte dysfunction in neurodegeneration, and experimental approaches to dopaminergic neuroprotection. We review findings reported in several papers including our own studies. We also address target molecules and pivotal pathways in astrocytes for dopaminergic neuroprotection. The review discusses new promising therapeutic strategies to prevent dopaminergic neurodegeneration in PD.

AB - Parkinson’s disease (PD) is one of common neurodegenerative diseases, which shows motor symptoms including tremor, bradykinesia, rigidity and postural instability. It also involves non-motor symptoms such as cognitive impairment, mental manifestation, autonomic disorder and sensory disturbance. Although treatments to improve the motor disability in PD are being assessed at present, the main challenge remains that is the development of neuroprotective or disease-modifying treatments. Therefore, it is desirable to find approaches that can inhibit the progression of dopaminergic neurodegeneration. Astrocytes are known to play an important role in the maintenance of the neuronal environment and exert neuroprotective effects. Additionally, astrocyte dysfunction increases the susceptibility of neurons to cytotoxicity. We have demonstrated neuroprotective approaches in parkinsonian models in various studies targeting astrocytes. In this article, we summarize the neuroprotective function of astrocytes in the brain, involvement of astrocyte dysfunction in neurodegeneration, and experimental approaches to dopaminergic neuroprotection. We review findings reported in several papers including our own studies. We also address target molecules and pivotal pathways in astrocytes for dopaminergic neuroprotection. The review discusses new promising therapeutic strategies to prevent dopaminergic neurodegeneration in PD.

KW - 5-hT1A receptor

KW - Antioxidative molecules

KW - Astrocyte

KW - Dopaminergic neuron

KW - Neuroprotection

KW - Nrf2

KW - Parkinson’s disease

KW - XCT

UR - http://www.scopus.com/inward/record.url?scp=85041640471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041640471&partnerID=8YFLogxK

U2 - 10.2174/1381612823666170710163731

DO - 10.2174/1381612823666170710163731

M3 - Review article

C2 - 28699520

AN - SCOPUS:85041640471

VL - 23

SP - 4936

EP - 4947

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 33

ER -